Biodefense: Nearness of Positive Government Initiatives
Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. The growth of the market is attributed to the some key driving factors such as presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. However, low R&D funding by government in developing and underdeveloped economies are expected to restraint the growth of the biodefense market during the forecast years.
Top Companies:
- Bavarian Nordic
- Alnylam Pharmaceuticals, Inc.
- SIGA Technologies
- Emergent BioSolutions Inc.
- Cleveland Bio Labs
- Dynavax Technologies
- Elusys Therapeutics, Inc.
- Soligenix
- Altimmune
- Pluristem Therapeutics
Every year, the government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks. For instance, in 2018, the US government released the National Biodefense Strategy and Implementation Plan, the National Security Strategy, the National Defense Strategy, and the National Counterterrorism Strategy, and the National Counter WMD Strategy, all of which include biosecurity and biodefense.
Enhances Influenza Vaccines and Health Security is the Budget which supports the Executive Order 13887, “Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health,” by providing a $95 million increase, compared to the 2020 enacted level, across Health and Human Services (HHS) for influenza vaccine manufacturing infrastructure and innovation; advanced research and development of improved vaccines, therapeutics, and diagnostics; international pandemic preparedness; and improved vaccine coverage nationwide.
As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. For instance, Antibiotic developer Spero Therapeutics has received $15.7 million in federal research funding from Biomedical Advanced Research and Development Authority for its oral carbapenem-class candidate, SPR994, to evaluate the drug’s effectiveness against biological threats, including anthrax, plague and melioidosis.
Source: The Insight Partners